The big picture: Traditional cancer diagnostics are notoriously slow, relying on complex biomarkers and isolated data that delay precision treatment. Waiv, a spinout from Owkin, is building an AI-powered system that reads cancer risks directly from routine pathology slides, delivering results in minutes rather than weeks.
Why it matters:
- Democratizing Precision: High-end genomic testing (NGS) is expensive and often unavailable in regional labs. Waiv’s models extract similar biological insights—like MSI and gBRCA detection—from standard H&E slides.
- Pharma Integration: The platform accelerates drug development by identifying eligible patients for clinical trials more efficiently, as evidenced by its existing R&D partnership with MSD.
- Dataset Advantage: Waiv leverages the PortrAIt consortium, one of Europe’s largest multi-institutional precision medicine datasets, to ensure its models remain robust across diverse populations.
How it works:
- Destra Platform: An interoperable lab system that provides automated risk scores for breast cancer and MSI detection with minimal workflow disruption.
- Multimodal Analysis: Combines digital pathology with clinical data to predict patient outcomes and biomarker responses at scale.
- Validated Tests: Includes RlapsRisk BC and BRCAura, which are designed to be “everyday ready” for clinical environments without requiring specialized hardware.
The catch: Waiv is entering a crowded field where giants like Tempus and PathAI have already secured significant market share. While its “all-in-one” approach of data plus validated tests is a strong differentiator, the company must overcome the “regulatory lag” inherent in medical AI. Much like the hurdles in digital screenings, Waiv’s success depends on proving its software-only proxies are as legally and clinically defensible as the physical biopsies they aim to supplement.
Key Details
- Funding: $33M (Series A)
- Lead: OTB Ventures, Alpha Intelligence Capital
- CEO: Meriem Sefta
- Sector: HealthTech / Biotech
